Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer
- 333 Downloads
The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies.
Patients had measurable disease defined by clinical examination or radiographic studies. Each cycle of treatment consisted of carboplatin at an AUC of 2 and paclitaxel at 80 mg/m2 on days 1, 8, and 15 of a 28-day cycle.
Twenty-eight patients with advanced or recurrent cervical and endometrial cancers were included in this study. The overall response rate (ORR) was 39% (2 CR, 9 PR). Among the 15 cervical cancers the ORR was 20%, while the 13 endometrial cancers had a 62% ORR. Median time to progression and overall survival was 3.4 and 7.6 months for those with cervical cancer and 5.5 and 15.4 months for those with endometrial cancer. Grade 3 or 4 hematologic toxicity was uncommon (7% grade 3 anemia, 21% grade 3 or 4 neutropenia, 7% grade 3 or 4 thrombocytopenia).
A regimen of weekly low-dose paclitaxel and carboplatin has an acceptable toxicity profile that is easily managed by dose adjustment and the use of erythropoietic therapy. This regimen appears to have activity in advanced or recurrent endometrial cancer which warrants further evaluation.
Key wordsEndometrial cancer Cervical cancer Chemotherapy
Unable to display preview. Download preview PDF.
- 1.American Cancer Society2004Cancer facts and figures 2004American Cancer SocietyAtlanta, GaGoogle Scholar
- 6.Markman, M 2000Weekly paclitaxel in the management of ovarian cancerSemin Oncol23740Google Scholar
- 17.Belani CP, Larocca RV, Rinaldi DA, et al. (2004) A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs standard paclitaxel and carboplatin given every 3 weeks, followed by weekly paclitaxel. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22:a7017Google Scholar
- 19.Seidman AD, Berry D, Cirrincione C, et al. (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22:a512Google Scholar
- 21.Rosenberg, P, Andersson, H, Boman, K, et al. 2002Randomized trial of single agent paclitaxel given weekly versus every 3 weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinumActa Oncologica41418424PubMedCrossRefGoogle Scholar